E Negretti|L Ferrari|V Bonfante|E Bajetta - JoVE Visualize

Showing results (101-110 of 549) with videos related to

Pageof 55

Sort By:

Journal of Trace Elements and Electrolytes in Health and Disease|December 1, 1991

Selenium status of children living in seleniferous areas of VenezuelaP Brätter, V E Negretti de Brätter, W G Jaffé, et al.

Les Cahiers De Prothese|June 1, 1991

[Rationale for fabrication of combination dentures]J L Ferrari

Medical Oncology (Northwood, London, England)|March 14, 2000

Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experienceS Viviani, P Notti, V Bonfante, et al.

Zentralblatt Fur Gynakologie|December 26, 2001

[A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer]H Sommer, B Pröhl-Steimer, E Bajetta, et al.

Tumori|July 30, 1999

Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility studyM Di Bartolomeo, E Bajetta, R Buzzoni, et al.

Anticancer Research|April 1, 2009

Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's diseaseF Villani, A Busia, M Villani, et al.

European Journal of Cancer & Clinical Oncology|May 1, 1985

Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVDS Viviani, A Santoro, G Ragni, et al.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1989

Hodgkin's disease: the Milan Cancer Institute experience with MOPP and ABVDG Bonadonna, P Valagussa, A Santoro, et al.

Tumori|August 31, 1992

Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acidM Colleoni, E Bajetta, F de Braud, et al.

Tumori|June 10, 1998

Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanomaE Bajetta, L Rimassa, C Carnaghi, et al.

Pageof 55

Showing results (101-110 of 549) with videos related to

Sort By:

Pageof 55

Journal of Trace Elements and Electrolytes in Health and Disease|December 1, 1991

Selenium status of children living in seleniferous areas of VenezuelaP Brätter, V E Negretti de Brätter, W G Jaffé, et al.

Les Cahiers De Prothese|June 1, 1991

[Rationale for fabrication of combination dentures]J L Ferrari

Medical Oncology (Northwood, London, England)|March 14, 2000

Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experienceS Viviani, P Notti, V Bonfante, et al.

Zentralblatt Fur Gynakologie|December 26, 2001

[A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer]H Sommer, B Pröhl-Steimer, E Bajetta, et al.

Tumori|July 30, 1999

Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility studyM Di Bartolomeo, E Bajetta, R Buzzoni, et al.

Anticancer Research|April 1, 2009

Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's diseaseF Villani, A Busia, M Villani, et al.

European Journal of Cancer & Clinical Oncology|May 1, 1985

Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVDS Viviani, A Santoro, G Ragni, et al.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1989

Hodgkin's disease: the Milan Cancer Institute experience with MOPP and ABVDG Bonadonna, P Valagussa, A Santoro, et al.

Tumori|August 31, 1992

Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acidM Colleoni, E Bajetta, F de Braud, et al.

Tumori|June 10, 1998

Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanomaE Bajetta, L Rimassa, C Carnaghi, et al.

Pageof 55